A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab and Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Cemiplimab (Primary) ; REGN 7075 (Primary) ; Fianlimab
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms EMPIRE
Most Recent Events
- 23 Jul 2025 New trial record